Connect with us


Dapagliflozin Misses Early Mark in COVID-19, but Kosiborod Sees Reasons for More Study – Managed Markets Network

The Dapagliflozin in Respiratory Failure in Patients With COVID-19 trial is the first phase 3 study to examine whether this SGLT2 inhibitor, which has proven effective…



Article feature image

A study that misses its mark would not typically generate this much interest, especially after trial sponsor AstraZeneca announced last month that results fell short of statistical significance. But with SGTL2 inhibitors gaining indications in heart failure and CKD, along with their original T2D approvalsconditions that put patients in danger when they get COVID-19many suspect this weekends results will not be the last word.
Since Kosiborod is one of the worlds leading experts on SGLT2 inhibitors,…

Click here to view the original article.

Continue Reading

You might also like ...

Article feature image
Study claims skipping morning meal can have ill-effects on health – Devdiscourse
Third wave of Covid ‘definitely under way’ in UK, says expert – The Guardian